Drug Profile


Alternative Names: DMDR; FCE 22723; Idamycin; Idarubicinol; IMI 30; NSC 256439; Zavedos; Zavedos Oral

Latest Information Update: 28 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class Antineoplastics; Cytostatic antibiotics; Daunorubicins
  • Mechanism of Action DNA cross linking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Acute nonlymphocytic leukaemia; Breast cancer; Leukaemia

Most Recent Events

  • 21 Oct 2013 Biomarkers information updated
  • 16 Apr 2003 Pharmacia Corporation has been acquired by, and merged into, Pfizer
  • 07 Sep 2000 Investigation in Chronic myeloid leukaemia (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top